ProPhase Labs (NASDAQ:PRPH) Shares Pass Below Two Hundred Day Moving Average – Time to Sell?

ProPhase Labs, Inc. (NASDAQ:PRPH) shares passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.26 and traded as low as $0.0750. ProPhase Labs shares last traded at $0.0756, with a volume of 4,041 shares traded.

ProPhase Labs Trading Up 0.8%

The business’s 50-day moving average price is $0.11 and its two-hundred day moving average price is $0.26. The company has a market capitalization of $455,263.20, a P/E ratio of -0.02 and a beta of 0.09. The company has a debt-to-equity ratio of 0.14, a current ratio of 0.14 and a quick ratio of 0.14.

Institutional Trading of ProPhase Labs

A hedge fund recently bought a new position in ProPhase Labs stock. XTX Topco Ltd acquired a new stake in ProPhase Labs, Inc. (NASDAQ:PRPH) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 102,506 shares of the company’s stock, valued at approximately $40,000. XTX Topco Ltd owned 0.25% of ProPhase Labs as of its most recent filing with the SEC. Institutional investors own 9.45% of the company’s stock.

ProPhase Labs Company Profile

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.